Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SLT v. Sharplan

This article was originally published in The Gray Sheet

Executive Summary

Surgical Laser Technologies, Inc. wins patent infringement suit against Laser Industries, Inc. subsidiary Sharplan. In a trial in the U.S. District Court for the Eastern District of Pennsylvania, a jury found that the majority of Sharplan's sapphire contact probes and scalpels, which are no longer sold in the U.S., infringe a family of SLT patents for its Contact Laser. In addition, the jury found that Sharplan's conical sculpted fibers, which are still sold in the U.S., infringe one of the Contact Laser patents. The jury also upheld the validity of the three SLT patents "that form the core of SLT's Contact Laser technology," SLT says, and concluded that SLT does not infringe a laser patent licensed by Sharplan from the University of Washington ("The Gray Sheet" May 6, 1991, I&W-7). Sharplan plans to introduce a substitute for the conical fibers, which constituted less that 1% of 1992 sales, and says that it will appeal the decision. Damages will be addressed in a subsequent proceeding.

You may also be interested in...

Orphan Indications In Medicare: Inspector General Will Examine Top-Selling Drugs

OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.


ATMPs Put EU Cross-Border Healthcare On The Map

Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts